Abstract

BackgroundIntermittent preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine (SP), provided as part of routine antenatal care (ANC), is one of three malaria-in-pregnancy prevention and control mechanisms recommended by the World Health Organization (WHO). However, despite high ANC attendance and increased efforts to address known obstacles, IPTp uptake figures have remained low. This study aimed to identify and assess barriers that continue to impede IPTp uptake in Uganda, in particular for women who attend ANC. The paper focuses on supply-side barriers, i.e., challenges relating to the health service provider.MethodsIn-depth interviews were conducted in two regions of Uganda in November 2013 and April/May 2014 with four different target audiences: seven district health officials, 15 health workers, 19 women who had attended ANC, and five opinion leaders. In addition, a document and record review was carried out at four health facilities.ResultsGuidelines with regard to IPTp provision in Uganda have been shown to be inconsistent and, at the time of the research, did not reflect the most recent WHO policy recommendation. There is a lack of training and supervision opportunities for health workers, resulting in poor knowledge of IPTp guidelines and uncertainty about the safety and efficacy of SP. ANC is not consistently offered in health facilities, leading to some women being denied services. While strengthening of the supply chain appears to have reduced the occurrence of stock-outs of SP in public facilities, stock-outs reportedly continue to occur in the private sector. There are also sources of data inaccuracy along the data recording and reporting chain, limiting policy makers’ ability to react adequately to trends and challenges.ConclusionsGiven the high ANC attendance rates in Uganda, supply-side barriers are likely to account for many missed opportunities for the provision of IPTp in Uganda. Improvements will require consistent provision of ANC, implementation of current WHO IPTp policy recommendations, supply of SP to the private sector, availability of clear guidelines, as well as improved training and supervision for health workers. Improving facility and district-level recording and reporting will further strengthen the country’s ability to address uptake of IPTp.Electronic supplementary materialThe online version of this article (doi:10.1186/s12936-016-1405-4) contains supplementary material, which is available to authorized users.

Highlights

  • Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine (SP), provided as part of routine antenatal care (ANC), is one of three malaria-in-pregnancy prevention and control mechanisms recommended by the World Health Organization (WHO)

  • This paper focuses on key challenges identified relating to supply-side issues, i.e., those challenges relating to the health service provider, including barriers relating to accessibility due to availability of services, affordability due to service charges, and acceptability from health workers’ point of view [9]

  • Stakeholders and coordination District officials in Eastern region listed a range of nongovernmental stakeholders with an interest in ANC and malaria in pregnancy

Read more

Summary

Introduction

Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine (SP), provided as part of routine antenatal care (ANC), is one of three malaria-in-pregnancy prevention and control mechanisms recommended by the World Health Organization (WHO). The World Health Organization (WHO) recommends three strategies for the prevention and control of malaria in pregnancy: (i) effective case management for malaria illness and anaemia; (ii) use of insecticide-treated nets; and, (iii) intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine (SP) [4]. IPTp involves the administration of curative doses of an anti-malarial drug to pregnant women residing in areas of moderate or high transmission in Africa, typically as part of the focused antenatal care (ANC) package. While SP is no longer recommended for the treatment of confirmed clinical cases of malaria, the drug is still considered the most efficacious anti-malarial for preventive use in pregnant women [5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call